Caristo was founded in 2018 by Cardiologists at the University of Oxford, following a decade of scientific research and technical development, and is now a leader in supporting the transformation of healthcare from treatment-based medicine to prevention. Caristo’s technology aims to revolutionise diagnosis and treatment, enabling physicians to identify patients with the highest heart attack risk and prescribe effective, personalised treatments that can prevent a fatal heart attack.
To date the company has raised a total of £10.2 million, they recently closed a successful investment round led by BGF and existing investors including Oxford Sciences Innovation (OSI), Longwall Ventures and the Oxford Technology & Innovation Fund (OTIF).
New products in the pipeline will also be capable of predicting stroke and diabetes risk, years in advance.
Business funding insights
BGF explains: How long should it take to prepare your business for investment?
Securing investment for your next stage of business growth takes preparation. Few businesses are investor-ready from the outset.
Founder Q&A: from bootstrapping to blooming growth
The founder of Bloom Procurement explains his vision for the business, why he chose BGF funding, and what he learned from the process